Multiple drugs

November 2017
Reactions Weekly;11/18/2017, Vol. 1678 Issue 1, p130
No abstract available.


Related Articles

  • Thalidomide Neuropathy. Rosenberg, Rhonda B. // Einstein Quarterly: Journal of Biology & Medicine;1998, Vol. 15 Issue 3, p158 

    Examines the development of a neuropathy that results from thalidomide, which is used as an immunolmodulatory agent. Benefits and adverse effects of thalidomide; Background on the origins and development of thalidomide.

  • Jekyll and Hyde: A new license for thalidomide? Saphir, Ann // JNCI: Journal of the National Cancer Institute;10/15/97, Vol. 89 Issue 20, p1480 

    Reports on the possibility of using thalidomide to keep cancer and a host of other diseases in check. Treatment of a serious skin disorder affecting lepers; Shrinkage of tumors; Treatment of Kaposi's sarcoma.

  • Thalidomide a success in one melanoma case.  // Dermatology Times;Nov2001, Vol. 22 Issue 11, p26 

    Reports the efficacy of thalidomide in patient with malignant melanoma in the United States. Enhancement on the response of the immune system to the disease; Elimination of the blood supply to tumor.

  • Thalidomide/topotecan.  // Reactions Weekly;2/20/2010, Issue 1289, p40 

    The article describes the case of two female patients who acquired hypomagnesaemia, fatigue, anemia and neutropenia while undergoing treatment with thalidomide and topotecan.

  • Antipruritic Action of Thalidomide. Daly, B. Martina; Shuster, Sam // Acta Dermato-Venereologica;Jan2000, Vol. 80 Issue 1, p24 

    The effect of thalidomide on itch was studied in 11 patients with chronic pruritus from psoriasis, eczema, nodular prurigo, senile pruritus and primary biliary cirrhosis. Itch, assessed subjectively by the patients on a 10 cm line and measured objectively as nocturnal scratch movement, was...

  • REPUTATION REHAB FOR AN INFAMOUS DRUG Thalidomide, Part II. MCLEAN, BETHANY // Fortune;9/29/1997, Vol. 136 Issue 6, p36 

    Reports on the attempts to legalize the use of thalidomide in the treatment of leprosy and immunological diseases such as AIDS. How the drug company Celgene would market thalidomide under the name Synovir; A meeting of the United States Food and Drug Administration advisory committee to discuss...

  • Thalidomide: Current Uses. Powell, R.J. // BioDrugs;1999, Vol. 11 Issue 6, p409 

    The major therapeutic effects of thalidomide are the selective inhibition of tumour necrosis factor-α production by monocytes and alteration in cellular surface expression of integrins. The major drawbacks of the drug are teratogenicity and irreversible axonal neuropathy. Despite the latter,...

  • Thalidomide.  // Reactions Weekly;10/9/2010, Issue 1322, p29 

    The article describes the case of an 88-year-old woman who acquired third-degree heart block while undergoing treatment with thalidomide.

  • Thalidomide back -- Under strict control. Marwick, Charles // JAMA: Journal of the American Medical Association;10/08/97, Vol. 278 Issue 14, p1135 

    Reports on the use of thalidomide as treatement of erythema nodosum leprosum (ENL) which is a complication of lepromatous leprosy. The drug having been studied for this use since 1965; The number of people in the United States affected by that complication of leprosy; The US Food and Drug...

  • Thalidomide for lesions in Hansen's disease. Rose, Verna L. // American Family Physician;11/15/1998, Vol. 58 Issue 8, p1907 

    Focuses on the approval given by the United States Food and Drug Administration (FDA) concerning the use of thalidomide for the treatment of skin lesions in person with Hansen's disease. Results of the clinical trials; Reasons cited by the FDA for imposing restrictions on thalidomide; Action...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics